Discontinuation of Mirabegron for Overactive Bladder
Mirabegron does not require tapering when the medication is being stopped for lack of benefit, because discontinuation is described as “stop” rather than a dose-reduction schedule in prescribing and patient materials. [1],[2] Abrupt discontinuation is also explicitly used for serious adverse reactions such as angioedema. [1]
Medication Selection Algorithm
- Continued mirabegron therapy is used when symptom control is adequate. [2]
- Mirabegron should be stopped when symptoms remain inadequately controlled despite appropriate use and dose level, and alternative therapies should be selected. [2]
- Alternative pharmacotherapy is typically selected from other OAB agents (beta-3 agonists or antimuscarinic therapy) or procedural options based on response and tolerability. [2]
Key Evidence Supporting This Recommendation
- The prescribing information instructs immediate discontinuation of mirabegron in cases of angioedema, which supports abrupt stopping when clinically indicated. [1]
Monotherapy vs Combination Therapy
- If mirabegron is used as monotherapy and becomes ineffective, switching to a different OAB pharmacologic strategy is recommended rather than tapering. [2]
- If mirabegron is used in combination with another OAB medication, discontinuation of mirabegron is still described as “stop” rather than tapering in regulatory and patient materials. [1],[2]
Important Clarifications or Nuances
- Mirabegron can cause increased blood pressure, urinary retention in patients with bladder outlet obstruction, and angioedema, each of which has management actions that include stopping the drug when clinically required. [1]
- For missed doses, the label describes skipping a missed dose when beyond the dosing window, which does not imply a need for tapering on discontinuation. [1]
Treatment Initiation Thresholds
- No taper initiation thresholds apply to mirabegron discontinuation in labeling or patient materials. [1],[2]
Common Pitfalls to Avoid
- Avoid continuing mirabegron solely because it was previously prescribed when it is ineffective, since discontinuation planning is addressed as a decision to stop therapy with the clinician. [2]
- Avoid delaying stopping when serious adverse reactions occur, since angioedema requires prompt discontinuation. [1]
Target Blood Pressure
- Blood pressure monitoring is recommended during therapy because mirabegron can increase blood pressure. [1]
- Blood pressure goals are not specified as a prerequisite for tapering versus abrupt discontinuation, because stopping is described without tapering. [1]